<DOC>
	<DOC>NCT02695420</DOC>
	<brief_summary>- To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction; - To evaluate the safety and tolerability of oral omecamtiv mecarbil</brief_summary>
	<brief_title>Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Japanese male or female ≥ 20 years and ≤ 85 years of age History of chronic stable HF with reduced ejection fraction, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening Reated for HF with optimal pharmacological therapy Left ventricular ejection fraction ≤ 40% at screening. Severe uncorrected valvular heart disease Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease Acute myocardial infarction, unstable angina, or persistent angina at rest within 30 days prior to randomization Systolic BP &gt; 160 mmHg or &lt; 90 mmHg, or diastolic BP &gt; 90 mmHg, or HR &gt; 110 beats per minute (bpm) or HR &lt; 50 bpm Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2 TBL ≥ 2x ULN, or ALT or AST ≥ 3x ULN Other Exclusion Criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>